Citi's downgrade of Novo Nordisk sent the company's shares lower today, a sign that Wall Street is starting to question how much longer GLP-1 demand can keep climbing. That reassessment landed the same day reporting surfaced on how unevenly these drugs are reaching patients, from a woman with a history of anorexia who was still prescribed a weight-loss injection, to Medicare beneficiaries who don't qualify for a promised discount. A separate study also suggested the timing of a first prescription may matter more than most people realize.
The sell-off in Novo Nordisk shares today followed a downgrade from a major bank, and it reflects a broader unease about whether GLP-1 sales can keep growing at the pace investors have grown used to. Novo has built its valuation on the assumption that demand for drugs like Wegovy will keep expanding, so any sign of deceleration tends to hit the stock hard. Today's move suggests that some investors are recalibrating those growth expectations rather than dismissing them outright. That reassessment does not change what is happening to patients who are already taking these drugs, but it does hint at how closely Wall Street is watching prescription trends.
One of those patient stories, reported today, involved a woman with a documented history of anorexia who was prescribed a weight-loss injection despite that history. The case raises a real question about how carefully prescribers are screening for eating disorder history before recommending an appetite-suppressing drug. GLP-1 medications work by reducing hunger and food intake, which is the intended effect for someone managing obesity but can be a serious risk for someone recovering from or vulnerable to disordered eating. If you or someone you know has a history of anorexia or another eating disorder, I would suggest raising that history directly with a prescriber before starting a GLP-1 medication, rather than assuming it will come up on its own.
A related gap exists in Medicare's own discount program for these drugs. The program was designed to make GLP-1 medications more affordable, but reporting today found that some sick patients don't actually qualify for the discount because of how the eligibility rules are written. That leaves a group of patients who need the drug for a covered condition but fall outside the specific criteria Medicare set, so they end up paying more than the discount was supposed to guarantee. For anyone relying on Medicare to cover or discount a GLP-1 prescription, I would suggest confirming eligibility directly with Medicare or a pharmacist before assuming the discount will apply.
Longer-term data suggests the calculus around starting a GLP-1 drug may look different depending on age. A new study reported today found that beginning GLP-1 treatment at 62 could add roughly a decade to life expectancy. That is a meaningful figure, and it suggests the benefit of starting treatment may be tied not just to weight loss itself but to how early in a person's health trajectory the drug is introduced. It is a reminder that decisions about starting or delaying a GLP-1 prescription are worth discussing with a doctor in the context of age and overall health, not just current weight.
That kind of long-term promise is part of what makes today's Citi downgrade notable by comparison. Citi's own explanation for cutting its rating on Novo Nordisk pointed specifically to slowing growth in GLP-1 demand, not to any single safety or eligibility issue reported elsewhere today. In other words, the bank's concern is about the pace of new prescriptions and market expansion, separate from the patient-level questions raised by the anorexia case or the Medicare discount gap. Investors reading today's downgrade should keep in mind that a slowdown in demand growth does not necessarily mean demand is shrinking, only that it may be leveling off from an unusually steep climb.
Today's news splits into two clear tracks. One track is financial: Citi's downgrade and Novo Nordisk's stock decline reflect how sensitive the GLP-1 market is to any sign of slowing growth. The other track is personal: the anorexia prescribing case and the Medicare discount gap both point to how much access to these drugs still depends on individual circumstances, not just broad approval. If you are considering a GLP-1 prescription, take the time to discuss your full health history with your prescriber and confirm your specific coverage details with Medicare or your insurer, rather than assuming general rules will apply to your situation.
Key details
Novo Nordisk's stock fell after a bank downgrade tied to concerns about slowing growth.
A woman with anorexia history was prescribed a weight-loss injection anyway.
The Medicare discount for GLP-1 drugs doesn't cover some sick patients who don't qualify.
Starting GLP-1 jabs at 62 could add a decade to life expectancy, a study suggests.
Citi cited slowing GLP-1 demand growth as the reason for its Novo Nordisk downgrade.
Read this on GLP-1 Nation: https://glp1nation.com/edition/36
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.